La píldora con 20 ug de etinilestradiol y 75 ug de gestodeno. Una nueva opción en anticoncepción oral de microdosis.

Autores/as

  • Jaime Urdinola

DOI:

https://doi.org/10.18597/rcog.1081

Palabras clave:

Anticonceptivos orales, etinil estradiol 20 ug, gestodeno 75 ug

Resumen

La píldora con 20 ug de Etinilestradiol (EE) y 75 ug de Gestodeno (GTD) aparece en 1998 como una nueva alternativa en Colombia para la anticoncepción, con una clara disminución de sus efectos secundarios y como consecuencia con una mejor tolerancia, sin perder la seguridad anticonceptiva y manteniendo adecuado control del ciclo. Es un paso adelante en el progreso y desarrollo de los Anticonceptivos Orales (AO), bienvenido no sólo por los médicos sino por sus pacientes.

 

Biografía del autor/a

Jaime Urdinola

Profesor de la Universidad El Bosque. Director Unidad de Climaterio y Menopausia. Hospital Simón Bolívar de Santafé de Bogotá.

Referencias bibliográficas

Urdinola J., Gutiérrez A., Londoño D. Anticonceptivos orales en América Latina. Adv Contracep 1993; 9 (Suppl. 1): 3-12.

Urdinola J. Anticonceptivos orales: 30 vs. 20 ug de etinilestradiol (EE). Adv Contrace.pt 1994; 10( Suppl. 1): 41-49.

Rabe T., Runnebaum B. Arzneirnittelpruefung von oralen Kontrazeptiva heute. En Hammerstein J (Ed): 25 Jahre hormonale Kontrazeptiva aus Berlin. Konsequente Dosisreduktion. Amsterdam, Excerpta Medica 1986; 62-72.

Inman WHW., Vessey MP. Investigation of deaths from pulmonary, coronary and cerebral thrombosis and embolism in Women of childbearing age. Br Med J 1968; 2: 193-199.

Cancer and Steroid Hormone Study of the Center for Disease Control and the National Institute of Child Health and Human Development: Combination oral contraceptive use and the risk of endometrial Cancer. J Am Med Assoc 1987; 257: 796-780.

Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: The reduction in risk of ovarian cancer associated with oral contraceptive use. N Engl J Med 1987; 316: 650-655.

Rosenberg MJ., Waugh MS., Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51: 283-288.

Gerstman BB., Piper JM., Tomita DK., Ferguson WL, Stadel BV., Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133: 32-37.

Vandenbroucke JP., van der Meer FJM., Helmerhorst FM., Rosendaal F. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996; 313: 1127-1130.

Mall-Haefeli M. Clinical experience with Mercilon and Marvelon with particular reference to ovarian function. Geburtsh Frauenheilk 1991; 51: 34-38.

Fitzergerald C., Feichtinger W., Spona J et al. A comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation. Adv Contracept 1994; 10: 5-18.

Elomaa K., Moorees MT., De Prest J., Lahteenmaki PO. Extension of the pill-free period by three days in oral contraceptive users. Abstract 04.27- The XIV FIGO World Congress, Montreal, September 1994.

Spona J., Elstein M., Feichtinger W., Sullivan H., Lüdicke Fm Müller U, Düsterberg B: Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996; 54: 71-77.

Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Combination oral contraceptive use and the risk of endometrial cancer. JAMA 1987; 257: 796-800.

Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of child Health and Human Development: The reduction in risk of ovarian cancer associated with oral contraceptive use. JAMA 1987; 316: 650-655.

Polatti R, Perotó R, Filippa N., Gallina D., Nappi RE. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception 1995; 51: 221-224.

Düsterberg B., Ellman H., Müller U., Rowe E., Mühe B. Three years' clinical experience with a new low-dose oral contraceptive containing 20 ug EE and 75 ug GTD: efficacy, cycle control and tolerability. En: Lopes Py Killick SR (Eds.): The New Option of Low-Dose Oral Contraception. Carnforth UK, The Parthenon Publishing Group 1996; 21-35.

Rosenberg MJ., Long SC. Oral contraceptives and cycle control. A critical review of the literature. Adv Contracept 1992; 8: (Suppl 1) 35.

Brill K., Müller C, Schnitker J., Albring M. The influence of different modern low-dose oral contraceptives on intermenstrual bleeding. Adv Contracept 1991; 7 (Suppl. 2): 51-61.

Latin American Oral Contraceptive Study Group: Clinical comparison of monophasic oral contraceptive preparations of gestodene / ethynilestradiol and desogestrel / ethynilestradiol. Contraception 1994; 50: 201-214.

Rosenberg MJ., Meehan T. The effect of desogestrel, gestodene, norgestimate and other factor on cycle control: a meta-analysis. Presentado en el Tercer Congreso de la Sociedad Europea de Anticoncepción, Dublin, 1994.

Short M., Endrikat J. A 12-month comparative investigation of reliability, cycle control and tolerance with low-dose oral contraceptives containing 20 ug ethynilestradiol and either 75 ug gestodene or 150 ug desogestrel. En: Lopes P y Killick SR (Eds.): The New Option of Low-Dose Oral Contraception. Carnforth UK, The Parthenon Publishing Group 1996; 37-47.

Cómo citar

1.
Urdinola J. La píldora con 20 ug de etinilestradiol y 75 ug de gestodeno. Una nueva opción en anticoncepción oral de microdosis. Rev. colomb. obstet. ginecol. [Internet]. 31 de diciembre de 1998 [citado 24 de abril de 2024];49(4):231-5. Disponible en: https://revista.fecolsog.org/index.php/rcog/article/view/1081

Descargas

Los datos de descargas todavía no están disponibles.

Descargas

Publicado

1998-12-31

Número

Sección

Revisión de Tema
QR Code

Métricas

Estadísticas de artículo
Vistas de resúmenes
Vistas de PDF
Descargas de PDF
Vistas de HTML
Otras vistas
Crossref Cited-by logo